6GPS image
Deposition Date 2018-06-07
Release Date 2019-01-02
Last Version Date 2024-11-20
Entry Detail
PDB ID:
6GPS
Title:
CRYSTAL STRUCTURE OF CCR2A IN COMPLEX WITH MK-0812
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.30 Å
R-Value Free:
0.29
R-Value Work:
0.24
R-Value Observed:
0.24
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:C-C chemokine receptor type 2,Rubredoxin,C-C chemokine receptor type 2
Gene (Uniprot):CCR2
Mutations:N14Q, C70Y, G175N, A241D, K311E,N14Q, C70Y, G175N, A241D, K311E,N14Q, C70Y, G175N, A241D, K311E,N14Q, C70Y, G175N, A241D, K311E,N14Q, C70Y, G175N, A241D, K311E,N14Q, C70Y, G175N, A241D, K311E,N14Q, C70Y, G175N, A241D, K311E,N14Q, C70Y, G175N, A241D, K311E,N14Q, C70Y, G175N, A241D, K311E
Chain IDs:A
Chain Length:429
Number of Molecules:1
Biological Source:Homo sapiens, Clostridium pasteurianum
Primary Citation
Crystal Structure of CC Chemokine Receptor 2A in Complex with an Orthosteric Antagonist Provides Insights for the Design of Selective Antagonists.
Structure 27 427 438.e5 (2019)
PMID: 30581043 DOI: 10.1016/j.str.2018.10.027

Abstact

We determined two crystal structures of the chemokine receptor CCR2A in complex with the orthosteric antagonist MK-0812. Full-length CCR2A, stabilized by rubredoxin and a series of five mutations were resolved at 3.3 Å. An N- and C-terminally truncated CCR2A construct was crystallized in an alternate crystal form, which yielded a 2.7 Å resolution structure using serial synchrotron crystallography. Our structures provide a clear structural explanation for the observed key role of residue E2917.39 in high-affinity binding of several orthosteric CCR2 antagonists. By combining all the structural information collected, we generated models of co-structures for the structurally diverse pyrimidine amide class of CCR2 antagonists. Even though the representative Ex15 overlays well with MK-0812, it also interacts with the non-conserved H1213.33, resulting in a significant selectivity over CCR5. Insights derived from this work will facilitate drug discovery efforts directed toward highly selective CCR2 antagonists with potentially superior efficacy.

Legend

Protein

Chemical

Disease

Primary Citation of related structures